Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT

Fig. 1

Immune reconstitution of CAEBV patients at 3, 6 and 12 months after haplo-HSCT. A CD3+ T cells; B CD4+ T cells; C CD8+ T cells; D NK cells; E B cells. CAEBV: chronic active Epstein-Barr virus infection; haplo-HSCT: HLA-haploidentical hematopoietic stem cell transplantation; Paired data was compared with Wilcoxon signed rank test. *: p < 0.05; n.s.: not significant

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172